Drug Profile

RC 3095

Alternative Names: D 21663; RC-3095

Latest Information Update: 08 Aug 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Tulane University
Developer AEterna Zentaris Inc
Class Antineoplastics
Mechanism of Action Gastrin-releasing peptide inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Cancer; Solid tumours

Most Recent Events

06 Aug 2024 AEterna Zentaris Inc is now called COSCIENS Biopharma
04 Aug 2005 This compound is still in active development for Cancer
01 Jun 2004 AEterna Laboratories is now called AEterna Zentaris

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com